Endocannabinoids in appetite control and the treatment of obesity
about
Cannabinoids in health and diseaseVagus nerve stimulation reduces body weight and fat mass in ratsEndocannabinoid system: emerging role from neurodevelopment to neurodegeneration.Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity.In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liabilityReceptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity.Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma.The PET radioligand [11C]MePPEP binds reversibly and with high specific signal to cannabinoid CB1 receptors in nonhuman primate brain.CB1 receptor antagonism blocks stress-potentiated reinstatement of cocaine seeking in rats.New targets for obesity pharmacotherapy.Endocannabinoid system and synaptic plasticity: implications for emotional responsesDissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice.Structure and physiological actions of ghrelinEmerging drugs for obesity therapy.The ghrelin/GOAT/GHS-R system and energy metabolism.Appetite control and obesity.The endocannabinoid system and appetite: relevance for food reward.G protein-coupled receptors in energy homeostasis.Proapoptotic effect of endocannabinoids in prostate cancer cellsA quick look at obesity; the enemy withinGhrelin and cannabinoids require the ghrelin receptor to affect cellular energy metabolism.Discriminative Stimulus Properties of the Endocannabinoid Catabolic Enzyme Inhibitor SA-57 in Mice.Pharmacokinetics, safety, and tolerability of phentermine in healthy participants receiving taranabant, a novel cannabinoid-1 receptor (CB1R) inverse agonist.Pharmacokinetics of digoxin in healthy subjects receiving taranabant, a novel cannabinoid-1 receptor inverse agonist.Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin.Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokinetics.Investigations of the human endocannabinoid system in two subcutaneous adipose tissue depots in lean subjects and in obese subjects before and after weight loss.
P2860
Q24633884-55E9BC9A-302A-446C-89A7-1382CE15C6AFQ28484122-3218EB45-0BB2-4BD8-948F-13230445DDF3Q30391852-C4EF7643-C24A-4B9B-B1EF-A3F5684FBCA7Q30493991-6DB16E1E-021A-4397-AE70-0E92BD502AD7Q33751118-020310AB-8DF5-4159-B14E-265C88AA3A31Q34110463-020F5EA0-CECB-4D92-87A2-687AC666E2A4Q34559890-49E42A17-B948-4311-80D8-F95B8629B8C4Q34613459-6C7A0485-E62C-42C7-ACAE-676F6B7229B7Q36436842-D8CC487F-595C-4D6E-B1FE-A943848AD0A0Q36793609-7F643DF4-54F2-496E-B07F-501057BAC238Q36887168-7DA7BA1D-ACAA-4C56-962D-8F1C69986CBBQ37001332-70F32D6D-CE2A-4536-BF64-013395EE259BQ37393063-7C3DBCAD-C850-4B72-8381-055D35EF4E7EQ37494328-EE4886E6-102C-43E3-BA97-C244275ECD31Q37845728-963E90B2-3C2E-42C9-9E73-704F953F63E6Q38022686-384F32AB-3B71-423E-B455-DB3456BB66A0Q38220568-BE385A41-9E5D-4DCE-BC01-5C4C28558C9CQ38223619-80202891-97A7-4E39-9126-A32BF92D5F74Q38918051-3C2F95C8-DB29-4267-8BB9-2F0982CD027AQ39489160-A7F973F8-1C4E-4EC9-B669-142477B59841Q42151441-777414E2-C95E-4CFB-8C47-1C955295C640Q42407000-8984411A-F05E-4A12-8341-8FF36988C837Q43270612-59E2ECE5-150F-4F06-A3BB-84FEE833257CQ46121154-0C846B5B-2C9A-4C48-9F55-477225354591Q46260487-E44BA4E4-E925-4181-9B1C-8FA021B440A5Q46308352-EA326D41-EC99-4C99-A4D2-7159F932A302Q47390763-DC747C82-211E-44EE-82B6-E8D9DF9E3DE9
P2860
Endocannabinoids in appetite control and the treatment of obesity
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Endocannabinoids in appetite control and the treatment of obesity
@ast
Endocannabinoids in appetite control and the treatment of obesity
@en
Endocannabinoids in appetite control and the treatment of obesity
@nl
type
label
Endocannabinoids in appetite control and the treatment of obesity
@ast
Endocannabinoids in appetite control and the treatment of obesity
@en
Endocannabinoids in appetite control and the treatment of obesity
@nl
prefLabel
Endocannabinoids in appetite control and the treatment of obesity
@ast
Endocannabinoids in appetite control and the treatment of obesity
@en
Endocannabinoids in appetite control and the treatment of obesity
@nl
P921
P1476
Endocannabinoids in appetite control and the treatment of obesity
@en
P2093
T C Kirkham
P304
P356
10.2174/187152706777452272
P407
P577
2006-06-01T00:00:00Z